Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03753919
Title Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Espanol de Tumores Neuroendocrinos

thyroid gland papillary carcinoma

thyroid gland Hurthle cell carcinoma

thyroid gland cancer

thyroid gland medullary carcinoma

thyroid gland follicular carcinoma

thyroid gland anaplastic carcinoma

differentiated thyroid gland carcinoma


Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.